Labcorp has been active in the biotech market with a series of strategic moves. It recently won a bid for select assets of Invitae, thereby expanding its footprint. The company has recently announced the possibility of acquiring assets from BioReference Health's Diagnostics Business and from Invitae. The EVP, Chief Legal Officer Sandra D van der Vaart, and CFO & Executive VP Glenn Eisenberg, have been noted selling shares, suggesting internal stakeholder moves. Labcorp underperformed but stock rose up, despite lagging the market. Labcorp announced mixed Q4 and Full Year 2023 Results and then its first Quarter 2024 earnings, following up by raising its 2024 EPS view. The company also declared a quarterly dividend. It benefited from strong trading days, outperforming its competitors. It still retains investors' confidence as they are advised to keep hold their Labcorp stocks. Interestingly, Labcorp rings with news of partnerships as seen with Philips, Hawthorne Effect and a strategic relationship with Baystate Health.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 03 Jul 2023 07:00:00 GMT to Thu, 16 May 2024 18:23:55 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor -3
